The firm brought in $1.6 billion from outside investors for its fifth main growth fund and separately promoted dealmaker Sri Rao. The credit-card company reported increases in profit and sales in the ...

As part of the transaction, HCRx Chairman and CEO Clarke Futch will continue to lead the HCRx team and will maintain an ongoing substantial minority interest in HCRx.

KKR’s deal is a bet that financing needs from drug companies will continue to rise. - Michael Nagle/Bloomberg News. KKR has ...

Investment firm KKR (KKR) announced on Wednesday the acquisition of a majority stake in the biopharma royalty acquisition company, HealthCare Royalty Partners.

KKR & Co. Inc., a leading global investment firm, today announced that it has acquired a majority ownership stake in HealthCare Royalty Partners (HCRx), a leading biopharma royalty acquisition company ...

Strengthens Board of Directors with appointment of two new independent members, increasing independent representation to greater than 90%Underscores Royalty Pharma’s commitment to enhanced corporate ...

XOMA Royalty’s acquisition of Turnstone Biologics highlights how royalty deals can revive biopharma companies and drive industry innovation.

MacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics’ cash runway extended through first half of 2027 ...

Additional information regarding the royalty purchase agreement is provided in a Current Report on Form 8-K filed by MacroGenics with the U.S. Securities and Exchange Commission.

MacroGenics and Sagard Healthcare Partners Enter into ZYNYZ® Royalty Purchase AgreementMacroGenics received $70 million upfront cash payment from Sagard Healthcare Partners (Sagard) MacroGenics’ cash ...

NEW YORK, June 04, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at the Goldman Sachs 46th Annual Global Healthcare ...

Healthcare Royalty Partners purchased anticipated royalties and milestone payments, and Regenxbio received $150 million upfront at closing.